RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of new data that confirms forodesine’s clinical activity in the treatment of chronic lymphocytic leukemia (CLL) at the 52nd Annual American Society of Hematology (ASH) Meeting & Exposition being held in Orlando, Florida.
